Glioblastoma (GBT) is the most prevalent and most aggressive form of cancers of the brain and nervous systems. GBT is a dismal disease with one year survival rates at 30% and five year survival rates at 3%.
Glioblastoma (GBT) is the most prevalent and most aggressive form of cancers of the brain and nervous systems. GBT is a dismal disease with one year survival rates at 30% and five year survival rates at 3%.
Trending Topic
Riccardo Soffietti (EAN Programme Committee; Chairman, Department of Neuro-Oncology, University and City of Health and Science Hospital, Turini, Italy) talks to us about the topic of the symposium he participated in entitled: Advances in molecular characterisation and personalised therapies in brain tumours. Part 2 of 2. Questions 1. What are the most promising agents targeting […]
Riccardo Soffietti (EAN Programme Committee; Chairman, Department of Neuro-Oncology, University and City of Health and Science Hospital, Turini, Italy) talks to us about the topic of the symposium he participated in entitled: Advances in molecular characterisation and personalised therapies in ...
EAN Programme Committee Member, Prof. Riccardo Soffietti, provides his insights on neuro-oncology coverage at this year’s EAN congress. Part 3 of 3. View Part 1 here. View Part 2 here. Speaker disclosures: nothing to disclose in relation to this video interview. Filmed at ...
EAN Programme Committee Member, Prof. Riccardo Soffietti, talks about unmet needs and what he considers will be the most exciting/promising developments in neuro-oncology over the next 2 years. Part 2 of 3. View Part 1 here. View Part 3 here. Speaker disclosures: nothing to ...
EAN Programme Committee Member, Prof. Riccardo Soffietti, discusses the most significant recent developments in neuro-oncology. Part 1 of 3. View Part 2 here. View Part 3 here. Speaker disclosures: nothing to disclose in relation to this video interview. Filmed at the 3rd Congress of ...
Dr Buckner (Mayo Clinic, Rochester, USA) presents, at a press conference at ASCO 2015, a federally funded phase III trial that is providing additional information regarding a long-standing discussion about the impact of adjuvant whole brain radiation therapy (WBRT) on cognitive ...
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.